Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CytomX Therapeutics has got two grants totaling more than $488,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program for its lead preclinical programs targeting colon, head and neck, pancreatic and triple-negative breast cancers and glioblastoma multiforme (GBM).
Subscribe to our email newsletter
CytomX CEO Nancy Stagliano said that following closely on the recent Series B financing, they believe these grants are another validation of the potential of their site-directed antibody development programs.
"We are very appreciative of the support provided by these grants and will use the funds to further advance our promising oncology program toward the clinic and achieve our mission of creating safer, more effective antibody therapies," Stagliano said said.